Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Page 1
[Adverse effects of long-term proton-pump inhibitor therapy on adults].
Igaz I, Simonyi G, Balogh S, Szathmári M. Igaz I, et al. Among authors: szathmari m. Orv Hetil. 2018 May;159(19):735-740. doi: 10.1556/650.2018.31057. Orv Hetil. 2018. PMID: 29730946 Review. Hungarian.
As these drugs are prescribed more and more frequently all over the world, the knowledge of the long-term adverse effects is very important not only for the specialists but for the general practitioners as well. In this review, the authors discuss the recent findings in th …
As these drugs are prescribed more and more frequently all over the world, the knowledge of the long-term adverse effects is very imp …
Influence of local exposure to static magnetic field on pain perception and bone turnover of osteoporotic patients with vertebral deformity - a randomized controlled trial.
Mészáros S, Tabák AG, Horváth C, Szathmári M, László JF. Mészáros S, et al. Among authors: szathmari m. Int J Radiat Biol. 2013 Oct;89(10):877-85. doi: 10.3109/09553002.2013.800249. Epub 2013 May 29. Int J Radiat Biol. 2013. PMID: 23627714 Clinical Trial.
RESULTS: Participants randomized to sham had higher VAS at baseline (mean difference: 2.8, 95% confidence interval (CI) 0.47-5.2 cm). Both SMF and sham similarly reduced short term pain (sham-SMF: 0.59, 95% CI - 0.31-1.49 cm, p = 0.195). VAS did not change in SMF, while it …
RESULTS: Participants randomized to sham had higher VAS at baseline (mean difference: 2.8, 95% confidence interval (CI) 0.47-5.2 cm). Both S …
High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification?
Kiss LS, Papp M, Lovasz BD, Vegh Z, Golovics PA, Janka E, Varga E, Szathmari M, Lakatos PL. Kiss LS, et al. Among authors: szathmari m. Inflamm Bowel Dis. 2012 Sep;18(9):1647-54. doi: 10.1002/ibd.21933. Epub 2011 Nov 13. Inflamm Bowel Dis. 2012. PMID: 22081542
CONCLUSIONS: Our data suggest that hs-CRP positivity at diagnosis is associated with disease location and behavior, and in patients who are hs-CRP positive at diagnosis, is an accurate marker of disease activity and a predictor of short- and medium-term clinical flare-ups …
CONCLUSIONS: Our data suggest that hs-CRP positivity at diagnosis is associated with disease location and behavior, and in patients who are …
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.
Kiss LS, Szamosi T, Molnar T, Miheller P, Lakatos L, Vincze A, Palatka K, Barta Z, Gasztonyi B, Salamon A, Horvath G, Tóth GT, Farkas K, Banai J, Tulassay Z, Nagy F, Szenes M, Veres G, Lovasz BD, Vegh Z, Golovics PA, Szathmari M, Papp M, Lakatos PL; Hungarian IBD Study Group. Kiss LS, et al. Among authors: szathmari m. Aliment Pharmacol Ther. 2011 Oct;34(8):911-22. doi: 10.1111/j.1365-2036.2011.04827.x. Epub 2011 Aug 24. Aliment Pharmacol Ther. 2011. PMID: 21883326 Free article.
BACKGROUND: Adalimumab is a fully human monoclonal antibody targeting tumour necrosis factor with proven efficacy in the treatment of Crohn's disease (CD). AIM: To investigate the predictors of medium-term clinical efficacy and mucosal healing during adalimumab therapy, in …
BACKGROUND: Adalimumab is a fully human monoclonal antibody targeting tumour necrosis factor with proven efficacy in the treatment of Crohn' …
[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
Kiss LS, Szamosi T, Molnár T, Miheller P, Lakatos L, Vincze A, Palatka K, Bartha Z, Gasztonyi B, Salamon A, Horváth G, Tóth GT, Farkas K, Banai J, Tulassay Z, Nagy F, Szenes M, Veres G, Lovász BD, Végh Z, Golovics PA, Szathmári M, Papp M, Lakatos PL. Kiss LS, et al. Among authors: szathmari m. Orv Hetil. 2011 Sep 4;152(36):1433-42. doi: 10.1556/OH.2011.29200. Orv Hetil. 2011. PMID: 21865144 Hungarian.
The aim of the present study was to investigate the predictors of medium term clinical efficacy and mucosal healing during adalimumab therapy in patients with Crohn's disease in specialized centers approved for biological therapy in Hungary. ...CONCLUSION: Clinical efficac …
The aim of the present study was to investigate the predictors of medium term clinical efficacy and mucosal healing during adalimumab …